Celgene’s Otezla hits primary endpoint in psoriatic arthritis study
pharmafile | November 15, 2016 | News story | Manufacturing and Production, Research and Development |Â Â Celgene, otezla, psoriatic arthritisÂ
Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment met its primary endpoint, improving ACR20 response at week 16 versus placebo in patients suffering from active psoriatic arthritis.
The data was generated in a study examining 219 patients who may have had one previous conventional therapy and had not previously been treated with a biologic. A separation between Otezla and placebo was observed at two weeks into the study as 16.4% of patients treated with Otezla achieved ACR20 versus 6.4% for those treated with placebo. This increased at week 16 with 38.2% of patients in the Otezla arm achieving ACR20 versus 20.2% for placebo.
At week 24 of the study, those in the placebo arm began treatment with Otezla; the study showed that patient responses in this group were maintained until week 52, whereas in those taking Otezla from baseline, ACR20 response increased to 67.1%.
“These findings show a separation from placebo as early as two weeks with oral Otezla in patients with psoriatic arthritis who have not been previously treated with biologics,” said Dr. Jacob Aelion, director of the West Tennessee Research Institute and clinical professor of Medicine/Rheumatology at the University of Tennessee in Memphis. “Early responses at week 2 across several measures of disease activity, including morning stiffness and enthesitis, were also seen at week 16.”
This new data in the psoriatic arthritis sphere coincides with the release of other efficacy evidence put forward by Novartis’ for its own treatment, Cosentyx.
Matt Fellows
Related Content
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, …
Abbvie psoriatic arthritis drug approved for use in Scotland
Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has …
NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …
